French off-patent association Gemme has made a bold show of support for pharmacy-level biosimilar substitution in a position statement published by the industry body. However, the proposals run against the views of broader European industry association Medicines for Europe and come against the backdrop of recently-adopted French legislation that ensures doctors will be involved in biologic substitution.
Biosimilars should be considered by doctors to be interchangeable with their original biologic brands and should be able to be substituted by pharmacists, under certain conditions, French off-patent industry association Gemme has declared in a position statement.
While it qualifies its recommendations by saying that such substitution should be limited to the initiation of treatment for certain...